Sonoma Pharmaceuticals Net Worth
Sonoma Pharmaceuticals Net Worth Breakdown | SNOA |
Sonoma Pharmaceuticals Net Worth Analysis
Sonoma Pharmaceuticals' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Sonoma Pharmaceuticals' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Sonoma Pharmaceuticals' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Sonoma Pharmaceuticals' net worth analysis. One common approach is to calculate Sonoma Pharmaceuticals' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Sonoma Pharmaceuticals' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Sonoma Pharmaceuticals' net worth. This approach calculates the present value of Sonoma Pharmaceuticals' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Sonoma Pharmaceuticals' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Sonoma Pharmaceuticals' net worth. This involves comparing Sonoma Pharmaceuticals' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Sonoma Pharmaceuticals' net worth relative to its peers.
Enterprise Value |
|
To determine if Sonoma Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sonoma Pharmaceuticals' net worth research are outlined below:
| Sonoma Pharmaceuticals is way too risky over 90 days horizon | |
| Sonoma Pharmaceuticals appears to be risky and price may revert if volatility continues | |
| Sonoma Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 12.73 M. Net Loss for the year was (4.83 M) with profit before overhead, payroll, taxes, and interest of 5.03 M. | |
| Sonoma Pharmaceuticals currently holds about 5.59 M in cash with (2.4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8. | |
| Sonoma Pharmaceuticals has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Analysts See Profit Pressure For Williams-Sonoma In 2025, But Brand Strength Remains Intact |
Sonoma Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Sonoma Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Sonoma Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of February 2024 Upcoming Quarterly Report | View | |
| 19th of June 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 19th of June 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
Sonoma Pharmaceuticals Target Price Consensus
Sonoma target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Sonoma Pharmaceuticals' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| One | Strong Buy |
Most Sonoma analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Sonoma stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Sonoma Pharmaceuticals, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationSonoma Pharmaceuticals Target Price Projection
Sonoma Pharmaceuticals' current and average target prices are 3.48 and 19.50, respectively. The current price of Sonoma Pharmaceuticals is the price at which Sonoma Pharmaceuticals is currently trading. On the other hand, Sonoma Pharmaceuticals' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Sonoma Pharmaceuticals Market Quote on 22nd of March 2025
Target Price
Analyst Consensus On Sonoma Pharmaceuticals Target Price
Know Sonoma Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sonoma Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sonoma Pharmaceuticals backward and forwards among themselves. Sonoma Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Sonoma Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ground Swell Capital, Llc | 2024-12-31 | 0.0 | Jane Street Group Llc | 2024-09-30 | 0.0 | Wells Fargo & Co | 2024-12-31 | 0.0 | Citigroup Inc | 2024-12-31 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 | Qube Research & Technologies | 2024-09-30 | 0.0 | Geode Capital Management, Llc | 2024-09-30 | 0.0 | Xtx Topco Ltd | 2024-09-30 | 0.0 | Two Sigma Securities, Llc | 2024-09-30 | 0.0 | Ubs Group Ag | 2024-12-31 | 17.4 K | Tower Research Capital Llc | 2024-12-31 | 2.4 K |
Follow Sonoma Pharmaceuticals' market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.85 M.Market Cap |
|
Project Sonoma Pharmaceuticals' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.30) | (0.31) | |
| Return On Capital Employed | (0.38) | (0.40) | |
| Return On Assets | (0.30) | (0.31) | |
| Return On Equity | (0.91) | (0.86) |
When accessing Sonoma Pharmaceuticals' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Sonoma Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sonoma Pharmaceuticals' profitability and make more informed investment decisions.
Please note, the presentation of Sonoma Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sonoma Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Sonoma Pharmaceuticals' management manipulating its earnings.
Evaluate Sonoma Pharmaceuticals' management efficiency
Sonoma Pharmaceuticals has return on total asset (ROA) of (0.1972) % which means that it has lost $0.1972 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6483) %, meaning that it created substantial loss on money invested by shareholders. Sonoma Pharmaceuticals' management efficiency ratios could be used to measure how well Sonoma Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of March 22, 2025, Return On Tangible Assets is expected to decline to -0.31. In addition to that, Return On Capital Employed is expected to decline to -0.4. At present, Sonoma Pharmaceuticals' Other Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 2.9 M, whereas Total Assets are forecasted to decline to about 15.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 7.76 | 7.38 | |
| Tangible Book Value Per Share | 7.76 | 7.38 | |
| Enterprise Value Over EBITDA | (0.05) | (0.05) | |
| Price Book Value Ratio | 0.41 | 0.43 | |
| Enterprise Value Multiple | (0.05) | (0.05) | |
| Price Fair Value | 0.41 | 0.43 | |
| Enterprise Value | 13.9 M | 13.2 M |
The management team at Sonoma Pharmaceuticals has a track record of steering the company towards sustained growth. Evaluating their strategies helps in understanding the stock's long-term potential.
Enterprise Value Revenue 0.0524 | Revenue | Quarterly Revenue Growth 0.136 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sonoma Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sonoma Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sonoma Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Mclaughlin John over six months ago Acquisition by Mclaughlin John of 20000 shares of Sonoma Pharmaceuticals at 1.08 subject to Rule 16b-3 | ||
Schutz James J over six months ago Disposition of 28 shares by Schutz James J of Sonoma Pharmaceuticals at 70.35 subject to Rule 16b-3 | ||
Dal Poggetto John over six months ago Acquisition by Dal Poggetto John of 15000 shares of Sonoma Pharmaceuticals subject to Rule 16b-3 | ||
Dal Poggetto John over six months ago Disposition of 1648 shares by Dal Poggetto John of Sonoma Pharmaceuticals at 175.5 subject to Rule 16b-3 | ||
Frederick Sandford over six months ago Acquisition by Frederick Sandford of 400000 shares of Sonoma Pharmaceuticals at 0.717 subject to Rule 16b-3 | ||
Bruce Thornton over a year ago Acquisition by Bruce Thornton of 60000 shares of Sonoma Pharmaceuticals subject to Rule 16b-3 | ||
Bruce Thornton over a year ago Acquisition by Bruce Thornton of 100000 shares of Sonoma Pharmaceuticals subject to Rule 16b-3 |
Sonoma Pharmaceuticals Corporate Filings
10Q | 5th of February 2025 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 30th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 20th of December 2024 Other Reports | ViewVerify | |
| 20th of September 2024 Other Reports | ViewVerify |
Sonoma Pharmaceuticals Earnings Estimation Breakdown
The calculation of Sonoma Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Sonoma Pharmaceuticals is estimated to be 0.0 with the future projection ranging from a low of 0.0 to a high of 0.0. Please be aware that this consensus of annual earnings estimates for Sonoma Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
0.00 Lowest | Expected EPS | 0.00 Highest |
Sonoma Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Sonoma Pharmaceuticals' value are higher than the current market price of the Sonoma Pharmaceuticals stock. In this case, investors may conclude that Sonoma Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Sonoma Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of March 2025 | Current EPS (TTM) | |
| 1 | 26.19% | -0.63 | 0.0 | -2.26 |
Sonoma Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Sonoma Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Sonoma Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Sonoma Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Sonoma Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Sonoma Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Sonoma Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Sonoma Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Sonoma Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-02-06 | 2024-12-31 | -0.6 | -0.63 | -0.03 | 5 | ||
2024-11-11 | 2024-09-30 | -1 | -0.59 | 0.41 | 41 | ||
2024-08-08 | 2024-06-30 | -0.06 | -0.07 | -0.01 | 16 | ||
2024-06-17 | 2024-03-31 | -0.17 | -0.07 | 0.1 | 58 | ||
2024-02-08 | 2023-12-31 | -0.21 | -0.08 | 0.13 | 61 | ||
2023-11-13 | 2023-09-30 | -0.24 | -0.29 | -0.05 | 20 | ||
2023-08-10 | 2023-06-30 | -0.12 | -0.2796 | -0.1596 | 133 | ||
2021-06-30 | 2021-03-31 | 0 | -0.5246 | -0.5246 | 0 | ||
2021-02-16 | 2020-12-31 | -0.72 | -0.32 | 0.4 | 55 | ||
2020-11-20 | 2020-09-30 | -1.18 | 0.06 | 1.24 | 105 | ||
2020-08-14 | 2020-06-30 | -0.91 | 0.54 | 1.45 | 159 | ||
2020-02-14 | 2019-12-31 | -0.72 | 12.72 | 13.44 | 1866 | ||
2019-11-14 | 2019-09-30 | -1.18 | -0.91 | 0.27 | 22 | ||
2019-08-13 | 2019-06-30 | -1.79 | 0.54 | 2.33 | 130 | ||
2019-06-30 | 2019-03-31 | -2.12 | -1.52 | 0.6 | 28 | ||
2019-02-14 | 2018-12-31 | -3.01 | -2.34 | 0.67 | 22 | ||
2018-11-08 | 2018-09-30 | -4.09 | -3.96 | 0.13 | 3 | ||
2018-08-08 | 2018-06-30 | -4.14 | -4.95 | -0.81 | 19 | ||
2018-06-13 | 2018-03-31 | -5.28 | -8.37 | -3.09 | 58 | ||
2018-02-07 | 2017-12-31 | -5.55 | -6.57 | -1.02 | 18 | ||
2017-11-09 | 2017-09-30 | -5.67 | -6.03 | -0.36 | 6 | ||
2017-08-08 | 2017-06-30 | -6.57 | -7.38 | -0.81 | 12 | ||
2017-06-05 | 2017-03-31 | -6.03 | -5.13 | 0.9 | 14 | ||
2017-02-09 | 2016-12-31 | 27.72 | 34.56 | 6.84 | 24 | ||
2016-11-10 | 2016-09-30 | -5.31 | -4.14 | 1.17 | 22 | ||
2016-07-28 | 2016-06-30 | -4.95 | -5.49 | -0.54 | 10 | ||
2016-06-16 | 2016-03-31 | -0.11 | -0.8 | -0.69 | 627 | ||
2016-02-04 | 2015-12-31 | -3.15 | -8.55 | -5.4 | 171 | ||
2015-11-05 | 2015-09-30 | -4.95 | -4.95 | 0.0 | 0 | ||
2015-07-30 | 2015-06-30 | -4.28 | -6.75 | -2.47 | 57 | ||
2015-06-11 | 2015-03-31 | -11.25 | 10.8 | 22.05 | 196 | ||
2015-02-12 | 2014-12-31 | -8.1 | -6.75 | 1.35 | 16 | ||
2014-11-13 | 2014-09-30 | -8.1 | -8.1 | 0.0 | 0 | ||
2014-08-07 | 2014-06-30 | -7.65 | -8.55 | -0.9 | 11 | ||
2014-06-12 | 2014-03-31 | -9.22 | -12.6 | -3.38 | 36 | ||
2014-02-13 | 2013-12-31 | -6.75 | -12.6 | -5.85 | 86 | ||
2013-11-19 | 2013-09-30 | -6.75 | -2.25 | 4.5 | 66 | ||
2013-08-08 | 2013-06-30 | -11.7 | -6.3 | 5.4 | 46 | ||
2013-06-13 | 2013-03-31 | -6 | -10.35 | -4.35 | 72 | ||
2013-02-13 | 2012-12-31 | -23.62 | -9.45 | 14.17 | 59 | ||
2012-11-01 | 2012-09-30 | 9.45 | -15.75 | -25.2 | 266 | ||
2012-08-02 | 2012-06-30 | -15.75 | -15.75 | 0.0 | 0 | ||
2012-06-07 | 2012-03-31 | -23.62 | -15.75 | 7.87 | 33 | ||
2012-02-02 | 2011-12-31 | -14.7 | -28.35 | -13.65 | 92 | ||
2011-11-03 | 2011-09-30 | -16.8 | -9.45 | 7.35 | 43 | ||
2011-08-04 | 2011-06-30 | -18.9 | -25.2 | -6.3 | 33 | ||
2011-06-02 | 2011-03-31 | -23.1 | -15.75 | 7.35 | 31 | ||
2011-02-03 | 2010-12-31 | -21 | -25.2 | -4.2 | 20 | ||
2010-11-04 | 2010-09-30 | -26.77 | -18.9 | 7.87 | 29 | ||
2010-08-05 | 2010-06-30 | -22.05 | -28.35 | -6.3 | 28 | ||
2010-02-04 | 2009-12-31 | -22.05 | -25.2 | -3.15 | 14 | ||
2009-11-05 | 2009-09-30 | -31.5 | -31.5 | 0.0 | 0 | ||
2008-11-06 | 2008-09-30 | -126 | -135.45 | -9.45 | 7 | ||
2008-08-05 | 2008-06-30 | -102.9 | -103.95 | -1.05 | 1 | ||
2008-06-11 | 2008-03-31 | -124.43 | -107.1 | 17.33 | 13 | ||
2008-02-07 | 2007-12-31 | -135.45 | -126.0 | 9.45 | 6 | ||
2007-11-12 | 2007-09-30 | -141.75 | -138.6 | 3.15 | 2 | ||
2007-08-09 | 2007-06-30 | -148.05 | -132.3 | 15.75 | 10 | ||
2007-06-07 | 2007-03-31 | -129.15 | -166.95 | -37.8 | 29 |
Sonoma Pharmaceuticals Corporate Management
| Jerome Dvonch | Interim Officer | Profile | |
| John Poggetto | Controller | Profile | |
| Jerome CPA | Chief Officer | Profile | |
| Victoria Covel | Assistant Controller | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonoma Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For information on how to trade Sonoma Stock refer to our How to Trade Sonoma Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonoma Pharmaceuticals. If investors know Sonoma will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonoma Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.26) | Revenue Per Share | Quarterly Revenue Growth 0.136 | Return On Assets | Return On Equity |
The market value of Sonoma Pharmaceuticals is measured differently than its book value, which is the value of Sonoma that is recorded on the company's balance sheet. Investors also form their own opinion of Sonoma Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Sonoma Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonoma Pharmaceuticals' market value can be influenced by many factors that don't directly affect Sonoma Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonoma Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonoma Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonoma Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.